Dyne Therapeutics, Inc.
Nasdaq: DYNPharmaceutical Preparations · Entity-resolved by Clous
Key financials
Short interest & fails
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The annual report describes a company with durable hardware franchises and a fast-growing, high-margin services segment. Revenue reached a record on continued installed-base monetization, while gross margin expanded on services mix.
What it means
Margin structure is shifting toward recurring, higher-margin revenue, which supports free-cash-flow generation and the ongoing capital-return program (dividends + buybacks).
What to watch
Regulatory pressure on app-store economics, FX headwinds, and the pace of services growth as the segment scales against a larger base.
Generated from public filings · not investment advice
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Net Income | -$168.1M | -$235.94M | -$317.42M | -$446.21M | -40.6% | — |
| Total Assets | $306.33M | $165.08M | $691.23M | $1.19B | +71.7% | — |
| Equity | $252.36M | $91.29M | $629.84M | $972.13M | +54.3% | — |
| Operating Cash Flow | -$153.65M | -$188.16M | -$292.37M | -$403.21M | -37.9% | — |
| Shares Outstanding | — | — | — | 113.12M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001818794